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Abstract
Background: Malaria is one of the most lethal and life-threatening killer infectious diseases in the world, and
account for the deaths of more than half a million people annually. Despite the remarkable achievement made in
preventing and eradicating malaria, it still remains a threat to the public health and a burden to the global
economy due to the emergence of multiple-drug resistant malaria parasites. Therefore, the need to develop new
anti-malarial drugs is crucial. The chemistry department at the University of Cape Town synthesized a number of
new CQ-like derivatives (TK-series), and evaluated them for in vitro activity against both CQ-sensitive and -resistant
Plasmodium falciparum strains, and for general cytotoxicity against a Chinese Hamster Ovarian (CHO) mammalian
cell line. The lead compounds from the TK-series were selected for a comprehensive pharmacokinetic (PK)
evaluation in a mouse model.
Methods: A sensitive LC-MS/MS assay was developed for the quantitative determination of TK900D. Multiple
reaction monitoring (MRM) in the positive ionization mode was used for detection. The analyte and the internal
standard (TK900E) were isolated from blood samples by liquid-liquid extraction with ethyl acetate. Chromatographic
separation was achieved with a Phenomenex® Kinetex C18 (100 × 2.0 mm id, 2.6 μm) analytical column, using a
mixture of 0.1% formic acid and acetonitrile (50:50; v/v) as the mobile phase. The method was fully validated over
concentrations that ranged from 3.910 to 1000 ng/ml, and used to evaluate the PK properties of the lead compounds
in a mouse model.
Results: The assay was robust, with deviation not exceeding 11% for the intra- and inter-run precision and accuracy.
Extraction recovery was consistent and more than 60%. PK evaluation showed that TK900D and TK900E have moderate
oral bioavailability of 30.8% and 25.9%, respectively. The apparent half-life ranged between 4 to 6 h for TK900D and 3.6
to 4 h for TK900E.
Conclusion: The assay was sensitive and able to measure accurately low drug levels from a small sample volume
(20 μl). PK evaluation showed that the oral bioavailability was moderate. Therefore, from a PK perspective, the
compounds look promising and can be taken further in the drug development process.
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Malaria, one of the world’s most serious and prevalent
infectious diseases, has been and remains responsible for
far more morbidity and mortality than most other dis-
eases, especially in Africa. It has been estimated that in
2010 there were approximately 219 million cases of mal-
aria that resulted in 660 000 deaths, 90% of which oc-
curred in Africa [1]. Even though there is a tremendous
increase in funding and intense momentum to reduce and/
or eradicate malaria infections, the disease still remains a
threat and an enormous burden on the global economy.
This is due to the emergence of multiple-drug resistance of
Plasmodium falciparum, the main cause of malaria infec-
tion in humans [1,2]. Therefore, the need to discover and
develop new anti-malarial drugs is imperative.
Chloroquine (CQ, Figure 1) was discovered by Hans
Andersag and co-workers in 1934, but was ignored for a
decade because it was considered toxic to humans. How-
ever, this notion changed when it was first introduced to
clinical practice as a prophylactic treatment for malaria
in 1947. Since then, and until the emergence of CQ-
resistant P. falciparum strains, CQ was considered as the
universal remedy for malaria and consequently a number
of potent anti-malarial compounds were developed that
were based on CQ core structure, i.e. the aminoquinoline
nucleus [3]. The emergence of P. falciparum strains that
were resistant to many drugs resulted in a serious limita-
tion in existing anti-malarials; this necessitated the devel-
opment of new anti-malarial drugs.
Several studies on the structure-activity relationship of
the aminoquinolines were undertaken in order to im-
prove their activity against drug-resistant P. falciparum
strains. Ridley et al. [4] and De et al. [5] observed that
shortening of the CQ alkyl side-chain length to 2 – 3
carbon atoms, and lengthening it to 10 – 12 carbon
atoms resulted in compounds that were active against
CQ-resistant P. falciparum strains. Stocks et al. [6] re-
ported that CQ derivatives in which the diethyl amino
function of the CQ’s side-chain was replaced by meta-
bolically more stable groups (such as tert-butyl, piperidyl
or pyrrolidino) led to a significant increase in anti-
malarial activity against the CQ-resistant strains. Ac-
cording to Iwaniuk et al. [7] modifying the length and
basicity of the CQ side chain, in particular the 4-amino-
7-chloroquinolines, with a linear side chain that con-
sists of two aliphatic tertiary amino functions, enhanced
the anti-malarial activity against both CQ-resistant
and -sensitive strains.
Thus encouraged by the aforementioned findings, the
Department of Chemistry at the University of Cape
Town designed and synthesized a number of new CQ-
like derivatives [8]. The design focused mainly on avoid-
ing the commonly observed metabolic N-dealkylation in
CQ-derivatives by incorporating bulkier substituents
such as the aromatic and tetrazole rings, while varying
the length of the alkyl side-chain (Figure 2).
All the synthesized CQ-like derivatives were evaluated
in vitro for potency against both CQ-sensitive (3D7) and
CQ-resistant (K1 and W2) strains of P. falciparum. The
in vitro antiplasmodial activity IC50 values for TK900D
were 0.0004, 0.0082, and 0.0305 μM against 3D7, K1 and
W2 strains respectively. Compared to CQ, TK900D was
less active (CQ IC50 0.0002 μM) against the CQ-sensitive
strain but significantly more active against the CQ-resistant
strains, K1 and W2 (IC50.values of CQ 0.036 and 0.0591 μM,
respectively).
Additionally, TK900D was found to be highly selective
towards Plasmodium infection based on the results ob-
tained from in vitro cytotoxicity test against a CHO mam-
malian cell line, using the 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazoliumbromide (MTT) assay (IC50 value of
10.5 μM). Thus, compound TK900D and its related com-
pound TK900E were selected as the lead compounds for
comprehensive PK evaluation as the evaluation of the PK
properties of the lead compounds is a prerequisite for lead
prioritization in the drug discovery and development
process.
In this paper, the development and validation of sensi-
tive and selective LC-MS/MS assay methods that can ac-
curately measure drug levels from a small extraction
volume (20 μl) of mice blood, and its application to the
evaluation of the PK properties of the compounds in a
mouse model is presented.
Methods
Chemicals and reagents
TK900D (C23H24Cl3N7, MW =504.85; Figure 3A) and
TK900E (C23H25Cl2N7, MW =470.40; Figure 3B) were
synthesized and their HPLC purity was determined to
be >99%. All chemicals and reagents used in this study
were of analytical grade or ACS (American Chemical
Society). Ammonium formate (97% pure) was purchased
from Sigma-Aldrich Gmbh (Steinheim, Germany), formic
acid (98 – 100%) was purchased from Merck KGaA
(Darmstadt, Germany), acetonitrile, ethyl acetate and
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Figure 1 Chloroquine.
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Figure 3 Structures of (A) TK900D; (B) TK900E (C) TK900C and (D) fragmentation pattern of TK900D.
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Honeywell, Burdick & Jackson (Muskegon, MI 49442,
USA). Water used to prepare solutions was purified by a
Millipore Elix 10 reverse osmosis and Milli-Q® (Millipore,
USA) Gradient A 10 polishing system.
Chromatography
HPLC analysis was performed with an Agilent 1200
infinity series quaternary pump which delivered the mo-
bile phase at a flow rate of 250 μl/min, combined with an
Agilent 1200 infinity series auto-sampler, degasser and
column compartment. The auto-sampler was equipped
with a 96-well plate and was used to inject 5 μls a m p l e s
onto the HPLC column. The Agilent cooling device was set
at 5°C. Chromatography was performed on a Phenomenex®
Kinetex C18 (100 × 2.0 mm id, 2.6 μm) analytical column
fitted with a Phenomenex® Security Guard™ System con-
taining a C18 (4 × 3 mm) pre-column. The column was
kept at 30°C with an Agilent 1200 infinity series column
compartment.
Detection
Analysis was performed on an AB SCIEX API 3200
triple quadrupole mass spectrometer (AB SCIEX, Toronto,
Canada) equipped with an electrospray ionization (ESI)
source operated at 550°C and set in the positive ion mode
for ion production. Transition of the protonated precursor
ions m/z 506 and m/z 472, to the product ions m/z 380
and m/z 346 for TK900D and the internal standard
(TK900E), respectively, were monitored at unit resolution
in the multiple reaction monitoring (MRM) mode with a
dwell time of 200 ms per transition. The curtain, nebulizer,
turbo, and collision gases were set at 20, 35, 35 and 3 psi,
respectively, while the ion spray voltage and the source
temperature were set at 2000 V and 550°C, respectively.
The declustering potential, collision energy, entrance po-
tential, and collision cell exit potential were optimized at
65, 35, 4, and 6 V respectively for TK900D; and 50, 33, 3,
and 6 V respectively for the internal standard. The instru-
ment was interfaced to a work station running Analyst™
version 1.5.2 software and all data generated was captured
and stored on the work station’s hard disc drive.
Preparation of calibration standards and quality control
samples
Human whole blood containing lithium heparin as anti-
coagulant was donated by volunteers at the clinical division
of PAREXEL International (South Africa) Bloemfontein. A
stock solution of TK900D at a concentration of 95.39 μg/ml
was prepared by dissolving 1.021 mg of TK900D in
10.703 ml of methanol (i.e. equivalent to 8.466 g of metha-
nol). A pool of human blood (5 g) was spiked with 50 μl
of TK900D stock solution to obtain a calibration standard
at upper limit of quantification (ULOQ) of 1000 ng/ml,
which was serially diluted with blank blood down to
3.910 ng/ml, the lower limit of quantification (LLOQ). A
different stock solution was prepared and the same meth-
odology was followed to prepare the quality control stan-
dards, which ranged from 3.910 to 800.0 ng/ml. Samples
were aliquoted (40 μl) in a 1.5 ml polypropylene microfuge
tubes and stored at approximately -80°C.
Sample preparation
Blood samples were completely thawed unassisted at
room temperature and briefly vortexed. Fifty microlitres
of a 20 mM ammonium formate buffer (pH 5.5) were
added to microfuge extraction tubes, 20 μl of the blood
sample was added, followed by the internal standard
(100 μl of 100 ng/ml TK900E in water). After a brief
vortex mixing of the sample, 1 ml of ethyl acetate was
added and vortexed for two minutes followed by centri-
fugation at 2000 g for five minutes at 4°C. The aqueous
phase was frozen in an alcohol freezing bath at ~ -20°C,
and the organic phase transferred into clean polypropyl-
ene tubes and evaporated to dryness (~ 40°C) under a
gentle stream of nitrogen gas. The residue was reconsti-
tuted with 200 μl of a 0.1% formic acid and acetonitrile
solution (50:50; v/v) and vortexed for 40 seconds. Ex-
tracts were transferred into a 96-well plate and 5 μlo f
the sample was injected onto the HPLC column.
Method validation
The method was validated according to the bioanalytical
method validation guidelines of the US Food and Drug
Administration [9] and the European Medicines Agency
[10] by analysing an appropriately prepared calibration,
and quality control standards in three consecutive
batches to demonstrate acceptable intra- and inter-batch
accuracy and precision over the desired range of concen-
tration. Quantification models based on peak areas and
peak area ratios were assessed to determine which model
performed the best for the statistical analysis of the val-
idation batches. A batch included all the calibration
standards in duplicate from 3.910 to 1000 ng/ml (LLOQ
to ULOQ), seven quality control standard levels span-
ning the concentration range from 3.910 (LLOQ) to
800.0 ng/ml (QC high) in replicates of six, six blanks,
two double blanks and three system performance verifi-
cation samples (SPVS) at the beginning, middle and end
of the batches.
Assay specificity
Blank human blood samples obtained from ten different
sources were tested for any visible interference.
Matrix effect
In order to evaluate the matrix effect on the ionization
of the analytes, blank human blood samples obtained
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high (800.0 ng/ml) and low (10.01 ng/ml) concentrations
of the analyte and one concentration of the internal
standard (100.0 ng/ml). These samples were injected to-
gether with samples containing no matrix components.
Linearity
Standard curves (n =3) of nine different concentration
levels of TK900D (3.910-1000 ng/ml), including blanks
(n =6) to control the carry-over and the presence of any
interferences, double blanks (n = 2) to ensure that the in-
ternal standard did not interfere with the quantification
of the analyte, and three system performance verification
samples to evaluate the instrument response over the
total run time, were extracted and assayed.
Inter-batch accuracy (% Nom) and precision (% CV)
The inter-batch accuracy and precision of the assay pro-
cedure were assessed by calculating the accuracy and
precision statistics of the seven levels of quality control
standards (n =6 per batch) over all three validation runs.
Extraction efficiency
Absolute recovery of the extraction procedure was assessed
by comparing the responses of spiked extracts with the
quality control standards (n=6) at high (800.0 ng/ml),
medium (160.1 ng/ml) and low concentrations (10.01 ng/ml)
of TK900D and at one concentration of the internal standard
(100.0 ng/ml) in whole blood.
Stability
Stock solution stability
The stability of TK900D and TK900E in methanol was
evaluated at room temperature, ~ 5°C and~ -20°C. Stock
solutions with concentrations of 100.0 μg/ml of TK900D
and the internal standard were prepared in methanol.
Three aliquots of each of the stock solutions were kept
at room temperature, ~ 5ºC, and~ –20°C, respectively,
for eight days. After diluting the stored stock solutions
in injection solvent to a 100.0 ng/ml, the stability of
TK900D and that of the internal standard were assessed
by comparing the peak areas obtained from the stored
stock solutions with peak areas of the freshly prepared
stock solutions. For stock solution results to be acceptable
the percentage reference value should not exceed 15%.
Long-term stability
For the determination of long-term stability in human
whole blood, TK900D spiked quality control samples at
800.0 ng/ml and 10.01 ng/ml were stored at ~ -80°C for
181 days (long enough to cover the time period elapsed
from the first day of sample collection to the final sample
analysis). These samples were thawed on the day of test-
ing and run together with freshly prepared calibration
standards and quality controls and the values were cal-
culated from the resulting calibration curve obtained
from the calibration standards.
Freeze and thaw stability
Quality control blood samples at high and low concentra-
tion, 800.0 and 10.01 ng/ml respectively, of TK900D stored
frozen at~-80°C were allowed to thaw completely un-
assisted at room temperature and then refrozen for 12 to
24 hours. After three such freeze-thaw cycles the samples
were assayed in the third validation run and the measured
concentrations were compared with the nominal concen-
trations of these samples.
Short-term (on-bench) stability
Quality control samples at high and low concentrations
(800.0 ng/ml and 10.01 ng/ml, respectively) of TK900D
were thawed completely unassisted at room temperature
and kept on bench for a period of time required to pre-
pare/extract the samples (~ 4 to 6 h.). The samples were
assayed in one of the validation batches. The measured
concentrations were compared with the nominal con-
centrations of these samples.
On-instrument stability
In order to assess the stability of the analytes while
awaiting injection on instrument, on-instrument stability
(OIS) was assessed for the period of time that the ex-
tracted samples were expected to stay on-instrument
during the batch run-time (~ 9 h). Quality control sam-
ples at high and low concentrations (800.0 ng/ml and
10.01 ng/ml, respectively), were extracted in replicates
of six and injected at the beginning and end of the run
(i.e. six QC-high and six QC-low at the beginning of the
run and another set of six QC-high and QC-low at the
end of the run bracketed with quality control samples).
The mean measured concentration of the OIS-samples
(injected at the end of the run) and OIS-reference samples
(injected at the beginning of the run) were compared: in
order to be acceptable, their percentage difference should
be within±15%.
Cross validation of human and mouse blood
According to the EMA Guidelines on Bio-analytical
Method Validation, 2012 [9], differences in sample prep-
aration, different matrices or the use of another analyt-
ical method may result in different outcomes between
the study sites. If possible, a cross-validation should be
performed in advance of the study samples’ analysis. For
cross-validation, the same set of QC samples or study sam-
ples should be analysed by different analytical methods or
by means of the same method using different matrices. For
QC samples, the obtained mean accuracy using the two
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15% and may be wider, if justified.
The efficacy and bioavailability studies were performed
in a mouse model [8], but due to the scarcity of mouse
blood, the method development and validation of the
LC-MS/MS assay were performed using human whole
blood. A cross validation by analysing the blood of mice
spiked with analytes at LLOQ, low, medium and high con-
centration levels (3.909, 10.01, 160.1 and 800.0 ng/ml) in
six fold against calibration standards and quality controls
prepared in human whole blood was performed to check
that the validation parameters will generate the same re-
sults (± 15% variation) in both matrices.
Results and discussion
LC-MS/MS optimization
Due to the presence of a number of amine groups in the
structures of TK900D and the IS an ESI in the positive
ionization mode was selected for ion production. After
collision-induced dissociation, the most abundant and
stable product ions were at m/z 379.8 for TK900D and at
m/z 346.0 for the IS (Figure 4). Thus, the MRM transitions
of m/z 506 →380 and m/z 472 →346 were selected for
TK900D and the IS respectively for the quantitative ana-
lysis. The mono-isotopic masses of TK900D and TK900E
are 503.1159 and 469.1548, respectively. As a result, the
masses of their protonated molecular ions were supposed
to be 504 and 470 but instead, 506 and 472 were obtained
during the setting up of the acquisition methods. During
Q1-scan, the infusion mass spectrum of TK900E shows
that the mass of the protonated molecular ion with the
most intense spectrum belongs to 470, followed by 472
and 471. However, during compound optimization and
the fragmentation process, the instrument selected the
protonated molecular ion with a mass of 472, as presented
in Figure 4B (MS/MS spectra of TK900E). This is due to
the presence of multiple chlorine atoms in both molecules
which has an influence on the multiplicity of the isotope
peaks [11]. The presence of more than one chlorine atom
in a molecule makes the multiplicity of the isotope peaks
more complex and the x+2 peak becomes more intense
(x stands for the mass of the protonated molecular ion
with the most abundant chlorine isotope,
35Cl, thus x +2
represents the mass of the protonated molecular ion
with
37Cl).
Six types of column, namely Discovery C18 (2.1 mm ×
150 mm, 5 μm), Discovery C8 (2.1 mm × 150 mm,
5 μm), Discovery Cyano (2.1 mm × 150 mm, 5 μm),
Kinetex C18 (2.0 mm × 100 mm, 2.6 μm), Luna C18
(2.0 mm × 150 mm, 5 μm), and Luna Phenyl Hexyl
(2.0 mm × 150 mm, 5 μm) were tested for chromato-
graphic parameters, such as retention time variability,
peak shape, resolution, etc. – and the best result was
obtained with Kinetex C18, followed by Discovery C18
and Luna C18 as a second and third choice, respectively.
For the optimal selection of the mobile phase, various
mixtures of solvents such as methanol, acetonitrile, and
methanol-acetonitrile (1:1, v/v) with volatile buffers such
as 0.1 to 0.5% formic acid and 20 mM ammonium for-
mate were tested to establish the efficiency of their MS
ionization, the variability of their retention time, and the
shape of the peak obtained. The best result was attained
with 0.1% formic acid-acetonitrile (50:50, v/v) as the mo-
bile phase at a flow rate of 250 μl/min.
Optimization of the injection solution was also done
by testing 0.1% formic acid, acetonitrile, and the mobile
phase as an injection solution. The mobile phase was
found to be the best injection solution which resulted in
the best shape of chromatographic peak with higher in-
tensity (best MS ionization) and a stable retention time.
The total run time was 2.5 minutes per sample. A rep-
resentative chromatogram of a calibration standard at
LLOQ is presented in Figure 5.
Sample preparation
Blood samples were processed by protein precipitation
with ice-cold acetonitrile and LLE with different organic
solvents, such as hexane-isoamyl alcohol (98:2; v/v), di-
ethyl ether, ethyl acetate, hexane-ethyl acetate (60:40; v/v)
and tert-butyl methyl ether (TBME). In addition to the
higher extraction recovery due to the cleaner extracts
obtained, LLE was preferred to protein precipitation.
Among the different organic solvents tested for sample
preparation, the best extraction efficiency (recovery) was
obtained with ethyl acetate. Extraction with and without
buffers at various pH values, were tested, and the best re-
sults were obtained with a 20 mM ammonium formate
buffer at pH 5.5.
Method validation
Assay specificity
Blank human blood samples obtained from ten different
sources were tested for any visible interference. A repre-
sentative chromatogram of a blank extract, as shown in
Figure 6, indicates that there was no interference, i.e. no
endogenous peaks at or near the retention time of the
analyte or the internal standard.
Linearity and LLOQ
The quantification of TK900D over the entire range,
3.910-1000 ng/ml was performed based on peak area ra-
tios using a Wagner calibration curve (ln(y) = a(ln(x))
2 +
b(ln(x)) +c) and r
2 of 0.9991. The cumulative results of
three representative standard curves for TK900D are
presented in Table 1.
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The within- and between-batch accuracy (% Nom) and
precision (% CV) of the assay procedure were assessed by
calculating the accuracy and precision statistics of the 7
levels of quality control standards (n=6 per batch) over
all three validation runs, as presented in Table 1. The
deviation is within±15% of the nominal value at all the
concentration levels. This indicates an acceptable accur-
acy and precision.
Extraction efficiency
The extraction recovery determined for TK900D was con-
sistent and repeatable. The results are presented in Table 2.
Figure 4 MS/MS spectrum of (A) TK900D; (B) TK900E (C) TK900C.
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A summary of the stability assessment is presented in
Table 3. This includes the analyte stability in stock solution,
freeze-thaw stability, on-bench stability, long-term stability,
and on-instrument stability. All the results showed that the
analyte was stable under the conditions in which the stabil-
ity assessment was performed, i.e.
 Both TK900D and the internal standard were stable
in methanol at all the storage temperatures (at room
temperature, 5°C, and -20°C);
 TK900D was stable in human whole blood for
181 days when stored at -80°C;
 TK900D was stable for at least three freeze-thaw
cycles;
 TK900D was stable for~ 12 h when left on-bench at
room temperature; and
 Both TK900D and the internal standard were stable
for~ 8.2 h on-instrument.
Cross validation
No significant differences were found between the sam-
ples prepared in human blood and in blood from mice.
This indicated that human blood could be used to pre-
pare calibration standards and quality control samples.
The results are presented in Table 4.
Matrix effect
It has been noted that co-eluting, undetected endogenous
matrix components may affect the ion intensity of the ana-
lyte and metabolite and adversely affect the reproducibility
and accuracy of the LC-MS/MS [12]. In order to determine
whether this effect (called the matrix effect) is present or
not, normal blank human blood from 10 different sources
was extracted, dried and reconstituted using solutions of
high (800.0 ng/ml) and low (10.01 ng/ml) concentrations
of the analyte and at one concentration of the internal
standard (100.0 ng/ml). These samples were injected
together with samples prepared in the reconstituted
solution at the same concentrations, containing no
matrix components.
The matrix effect is quantitatively measured by cal-
culating the Internal Standard-Normalized Matrix Fac-
tor (IS-MF), which is the Peak Area Ratio in the
Presence of Matrix Ions for each blood sample divided
by the mean of the Peak Area Ratio in the Absence of
Matrix Ions.
A matrix factor (MF) of one signifies no matrix effect,
while a value of less than one suggests the suppres-
sion of ionization. A value that is greater than one signi-
fies ionization enhancement [13]. An absolute Internal
Standard-Normalized MF of one is not required for a reli-
able analytical assay. However, the variability (% CV) in
Figure 5 Representative chromatogram of TK900D at LLOQ.
Figure 6 Representative chromatogram of TK900D blank human whole blood extract.
Abay et al. Malaria Journal 2014, 13:42 Page 8 of 13
http://www.malariajournal.com/content/13/1/42matrix factors should be less than or equal to 15% to en-
sure reproducibility of the analysis.
The internal standard normalized matrix factor as cal-
culated for this particular paper showed no significant
ion suppression or enhancement at high and low con-
centrations of TK900D. The variability (% CV) was 2.6%
and 2.8% at 800.0 ng/ml and 10.01 ng/ml, respectively,
which indicates that sample analysis was reproducible.
Pharmacokinetic evaluation of TK900D
Snapshot pharmacokinetic evaluations were performed on a
number of analogues from the TK-series anti-malarial com-
pounds. TK900D showed to be one of the most promising
compounds from a pharmacokinetic perspective, and
was selected for comprehensive pharmacokinetic evalu-
ation. The test compound dissolved in a 20 mM Sodium
acetate buffer (pH 4.0): Ethanol: PEG400 (70:5:25; v/v/)
drug vehicle was administered orally to healthy C57/
BL6 mice (n = 5) at doses of 40 and 20 mg/kg, and intra-
venously at doses of 5 and 2.5 mg/kg. Blood samples
were collected at predetermined sampling times (except
for the first sampling time, i.e. 5 minutes after dosing
for the IV group and 10 minutes for the oral group,
the sampling times were 0.5,1, 3, 5, 7, 12 and 24 h
after dosing) by bleeding the tip of the tail, and ana-
lysed using a validated LC-MS/MS assay. Back-calculated
concentrations of the blood samples were obtained from
a standard regression curve with nine concentration
levels (3.910 to 1000 ng/ml). Concentration vs. time
profiles were constructed and the data analysed with
Summit PK software to obtain the pharmacokinetic
parameters.
The pharmacokinetic parameters are presented in
Table 5 and the blood drug concentration vs. time pro-
files (mean of n =5) are presented in Figure 7.
The apparent half-life for TK900D ranged from 2 to 6 h.
The volume of distribution was high (8.9 l/kg at 5.0 mg/kg,
and 7.9 l/kg at 2.5 mg/kg doses) and the blood clear-
ance moderate (44.8 ml/min/kg at 5.0 mg/kg, and 48.9 at
2.5 mg/kg doses). The mean blood drug concentrations
Table 1 Cumulative statistics of TK900D calibration standards and quality control samples
Parameters Calibration standards and nominal concentrations (ng/ml)
STD B STD C STD D STD E STD F STD G STD H STD I STD J
3.910 7.821 15.64 31.28 62.57 125.0 250.0 500.2 1000
Mean 4.051 7.524 15.48 30.94 64.10 126.6 251.7 496.6 996.3
% Nom 103.6 96.2 99.0 98.9 102.5 101.3 100.7 99.3 99.6
%C V 3.4 4.3 1.7 3.9 2.2 1.9 0.6 0.9 0.9
% Bias 3.6 -3.8 -1.0 -1.1 2.5 1.3 0.7 -0.7 -0.4
N 6666 6 666 6
Parameters Quality control samples and nominal concentration (ng/ml)
QC A QC B QC C QC D QC E QC F QC G QC H DIL
3.909 10.01 20.01 60.03 160.1 400.2 800.0 1600
LLOQ Low ———— ———— Medium ———— High Dilution
Mean 3.815 10.12 21.13 63.42 177.5 436.2 840.9 1673
% Nom 97.6 101.1 105.6 105.7 110.9 109.0 105.1 104.6
%C V 10.8 5.3 4.5 5.4 5.7 7.1 8.3 5.1
% Bias -2.4 1.1 5.6 5.7 10.9 9.0 5.1 4.6
N 18 18 18 18 18 18 18 6
QCH DIL was used to establish the dilution linearity of the method.
Table 2 Absolute recovery, using response factor
Sample Analyte
conc. (ng/ml)
Mean of peak areas Absolute
recovery (%)
CV
(%) After extraction Theoretical values
High conc. 800.0 825850 1120664 73.7 4.3
Medium conc. 160.1 169317 260280 65.1 4.5
Low conc. 10.01 10482 14370 72.9 8.9
Mean 70.6 5.9
ISTD 100.0 418683 543089 77.1 2.8
N.B.: The concentration of the ISTD was same at high, medium and low concentration levels.
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256 min.μmol/l for the high and low doses respectively.
One would expect that by doubling the dose the Cmax and
AUC would increase significantly, but this was not ob-
served – possibly indicating that the rate of solubility or
dissolution limited the absorption at higher doses. The
oral bioavailability of the drug in the groups that received
relatively high doses (oral at 40 mg/kg, and IV at 5 mg/kg)
was 16.2%, and the oral bioavailability of the drug in the
groups that had relatively low doses (oral at 20 mg/kg,
and IVat 2.5 mg/kg) was 30.8%.
According to the MMV (Medicines for MalariaVenture)
compound progression criteria of August 2008 [14], a
compound with oral bioavailability>20% in rat after oral
dosing is considered as a development candidate. There-
fore, the oral bioavailability of TK900D in a mouse model
looks promising.
Pharmacokinetic evaluation of TK900E
TK900E, another CQ-like derivative in this chemical
series, was evaluated for its PK properties in a mouse
model. The in vitro IC50 values in both the CQ-sensitive
(3D7) and -resistant (K1 & W2) P. falciparum strains
were 0.002, 0.001 and 0.0255 μM, respectively. Thus, an-
other LC-MS/MS method using the same LC conditions
and extraction procedure as for TK900D, was developed
and fully validated for TK900E, using TK900C (Figure 3C)
as an internal standard (mass spectrum of TK900C is pre-
sented in Figure 4C). The validated method was used to
evaluate the pharmacokinetic properties of TK900E in a
mouse model and the results are presented in Table 5.
The blood drug concentration vs.t i m ep r o f i l e s( m e a no f
n=5) data is presented in Figure 8.
The apparent half-life for TK900E ranged between 1.6
to 4 h. The volume of distribution was high (10.3 l/kg at
Table 3 Stability assessment
Stability Analyte code Mean analyte peak area (n=6)
Room temperature ~ 5°C ~ -20°C Fresh (reference)
Analyte stock solution stability in methanol TK900D Peak area 813083 800550 762900 760700
% Reference 106.9 105.2 100.3 N/A
%C V 2.9 1.4 2.4 1.8
TK900E Peak area 876300 881567 836667 852133
% Reference 102.8 103.5 98.2 N/A
%C V 1.9 2.8 2.2 2.9
Stability TK900D Nominal concentration (ng/ml)
High (800.0) Low (10.01)
Long term Mean 805.7 9.598
%C V 6.9 11.9
% Bias 0.7 -4.0
Freeze and thaw Mean 852.7 10.87
%C V 5.8 8.9
% Bias 6.6 8.6
On bench Mean 866.0 10.53
%C V 3.4 7.5
% Bias 8.3 5.2
OIS Mean 806.9 10.46
%C V 0.6 1.4
% Bias 0.9 4.5
All results are mean of n = 6.
Table 4 Cross validation result summary for TK900D
Species Human Mouse Human Mouse Human Mouse Human Mouse
Nominal conc. (ng/ml) 800.0 800.0 160.0 160.0 10.00 10.00 3.906 3.906
Mean (n= 6) 809.2 899.3 160.8 185.7 9.889 10.66 3.912 3.946
%C V 7.5 5.4 8.2 5.6 9.1 12.2 9.4 11.9
% Bias 1.2 12.4 0.5 16.1 -1.1 6.6 0.2 1.0
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Parameters TK900D TK900E
Oral
a IV
a Oral
a IV
a
Nominal dose (mg/kg) 40 20 5.0 2.5 40 20 5.0 2.5
Apparent t1/2 (h) 3.9 6.0 2.3 1.9 4.0 3.6 2.5 1.6
Blood CLtotal (ml/min/kg) —
b —
b 44.8 48.9 —
b —
b 51.0 51.2
Vd (l/kg) —
b —
b 8.9 7.9 —
b —
b 10.3 7.0
Vss (l/kg) —
b —
b 9.1 8.7 —
b —
b 12.6 6.5
Cmax (μM) 0.79 0.54 —
b —
b 2.81 0.94 —
b —
b
Tmax (h) 1.4 1.4 —
b —
b 1.0 0.8 —
b —
b
AUC0-∞ (min. μmol/l) 287 256 222 104 541 222 221 107
Bioavailability (%) 16.2 30.8 —
b —
b 30.6 25.9 —
b —
b
aValues are the mean of 5 animals,
bEmpty cells indicate that the value was measured or was not relevant.
Figure 7 Mean blood concentration vs. time profiles of TK900D following the administration of (A) 40 and 20 mg/kg TK900D orally
and (B) 5 and 2.5 mg/kg TK900D intravenously to healthy male C57BL/6 mice (n=5).
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http://www.malariajournal.com/content/13/1/425.0 mg/kg, and 7.0 l/kg at 2.5 mg/kg doses) and the blood
clearance moderate (51.0 ml/min/kg at 5.0 mg/kg, and
51.2 at 2.5 mg/kg doses).
The mean blood drug concentrations were 2.81 μM
and 0.94 μM, and the AUC was 541 and 222 min.μmol/l
for the high and low doses, respectively, indicating a dose-
dependent relationship (doubling the dose nearly doubles
the response in concentration and AUC).
The oral bioavailability of the relatively high dose groups
(oral at 40 mg/kg, and IV at 5 mg/kg) was 30.6%, and the
oral bioavailability at the relatively low dose groups (oral
at 20 mg/kg, and IVat 2.5 mg/kg) was 25.9%.
Conclusion
Robust LC-MS/MS methods were developed and vali-
dated for the quantification of TK900D and TK900E in
blood, using a very small extraction volume (20 μl).
The reported method offers an advantage of rapid and
simple liquid-liquid extraction, together with a short chro-
matographic run time. This makes the method suitable for
the analysis of large sample batches without any loss in
instrument performance. The signal-to-noise ratios (S/N)
at the pre-set LLOQ value of 3.910 ng/ml, were 30 and 20
for TK900D and TK900E respectively. The S/N ratio indi-
cates that the methods were highly sensitive; even though a
small volume of extraction (20 μl) was used. The methods
were successfully used to evaluate the pharmacokinetic pa-
rameters of TK900D and TK900E in a mouse model.
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